This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PCMA: Biotech Manufacturers Lobby States To Restrict Access To Biosimilar Medications

Drugmakers Take on Employers, Patients Who Want Lower Health Care Costs

WASHINGTON, Jan. 31, 2013 /PRNewswire-USNewswire/ -- Some biotech drug manufacturers are lobbying state legislators to restrict access to biosimilar (or biogeneric) versions of expensive brand medications, the Pharmaceutical Care Management Association (PCMA) said today.  Such proposals would increase costs for employers, public health programs, and patients, and restrict access to lower cost alternatives.

A recent New York Times article uncovered the campaign, which seeks to protect expensive biologic rheumatoid arthritis, psoriasis, and cancer treatments from generic (biosimilar) competition.  Many of the brand versions of these medicines cost "tens or even hundreds of thousands of dollars a year."

A pathway for the Food and Drug Administration (FDA) to approve generic versions of biologic products was passed in the Affordable Care Act.  Currently, the FDA is in the process of developing this pathway for approval of biosimilars and determining "interchangeability" for the new products. 

This campaign is designed to preempt the FDA's process by creating a flurry of state laws that will conflict with the FDA's forthcoming national standards.  Creating a patchwork of dueling state and federal rules would make it harder for pharmacists to know when they can dispense a biosimilar.  That would raise costs for patients and their employers, who typically cover two-thirds of prescription drug benefit costs. 

"Campaigning to restrict the use of biosimilars enriches brand manufacturers at the expense of the employers, public health programs, and patients who need access to lower cost medicines," said PCMA President and CEO Mark Merritt.

Legislation is currently pending in 10 states including Arkansas, Colorado, Florida, Indiana, Massachusetts, Mississippi, North Dakota, Texas, Virginia, and Washington.

PCMA represents the nation's pharmacy benefit managers (PBMs), which improve affordability and quality of care through the use of electronic prescribing (e-prescribing), generic alternatives, mail-service pharmacies, and other innovative tools for 215 million Americans.

Follow PCMA on Twitter

SOURCE Pharmaceutical Care Management Association

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs